88 results on '"Petteway S"'
Search Results
2. Critical factors influencing prion inactivation by sodium hydroxide
3. Evaluation of virus and prion reduction in a new intravenous immunoglobulin manufacturing process
4. Tracking the partitioning of the pathogenic form of the human prion protein during plasma fractionation using a sensitive Western blot assay
5. Pathogen safety of manufacturing processes for biological products: special emphasis on KOGENATE® Bayer
6. Synthesis of a novel hematopoietic peptide, SK&F 107647
7. Viruses as vectors for cysteine proteases
8. ChemInform Abstract: Synthesis and Antiviral Activity of a Novel Class of HIV-1 Protease Inhibitors Containing a Heterocyclic P1′-P2′ Amide Bond Isostere.
9. Effect of a single amino acid substitution in the V3 domain of the human immunodeficiency virus type 1: generation of revertant viruses to overcome defects in infectivity in specific cell types
10. Antiretroviral activities of protease inhibitors against murine leukemia virus and simian immunodeficiency virus in tissue culture
11. Effect of retroviral proteinase inhibitors on Mason-Pfizer monkey virus maturation and transmembrane glycoprotein cleavage
12. Human immunodeficiency virus type 1 protease inhibitors irreversibly block infectivity of purified virions from chronically infected cells
13. Binding of soluble CD4 proteins to human immunodeficiency virus type 1 and infected cells induces release of envelope glycoprotein gp120.
14. Synthetic Inhibitors of HIV-1 Protease Block Processing of Pr55gagand Pr160gag-po1Polyproteins in Infected T Lymphocytes
15. Ultrastructural and Cytochemical Analysis of the Loss of Envelope Glycoproteins (gp120) on Budding and Mature HIV-1 following Treatment with Soluble T4 (sT4)
16. Simple method to predict digoxin serum concentration.
17. Ultrastructural and Cytochemical Analysis of the Loss of Envelope Glycoproteins (gp120) on Budding and Mature HIV-1 following Treatment with Soluble T4 (sT4).
18. Synthetic Inhibitors of HIV-1 Protease Block Processing of Pr55gag and Pr160gag-po1 Polyproteins in Infected T Lymphocytes.
19. Antibodies reactive with human immunodeficiency virus gag-coded antigens (gag reactive only) are a major cause of enzyme-linked immunosorbent assay reactivity in a blood donor population
20. Effects of SKF 108922, an HIV-1 protease inhibitor, on retrovirus replication in mice
21. Structure−Activity Relationships of Novel Hematoregulatory Peptides
22. Expression and site-specific mutagenesis of the poliovirus 3C protease in Escherichia coli.
23. Purification and properties of thiol beta-lactamase. A mutant of pBR322 beta-lactamase in which the active site serine has been replaced with cysteine.
24. Evaluation of TSE clearance by the filtration process of a new intravenous immunoglobulin product (Gamunex™, 10%)
25. HIV-1-specific production of IFN-gamma and modulation by recombinant IL-2 during early HIV-1 infection.
26. Analysis of Human Serum Antibodies to Human Immunodeficiency Virus (HIV) Using Recombinant ENV and GAG Antigens
27. ChemInform Abstract: Synthesis and Antiviral Activity of a Novel Class of HIV-1 Protease Inhibitors Containing a Heterocyclic P1′-P2′ Amide Bond Isostere.
28. Immunoglobulin replacement therapy in primary antibody deficiency diseases--maximizing success.
29. Enveloped virus inactivation by caprylate: a robust alternative to solvent-detergent treatment in plasma derived intermediates.
30. Pathogen safety of manufacturing processes for biological products: special emphasis on KOGENATE Bayer.
31. Ensuring the pathogen safety of intravenous immunoglobulin and other human plasma-derived therapeutic proteins.
32. A direct relationship between the partitioning of the pathogenic prion protein and transmissible spongiform encephalopathy infectivity during the purification of plasma proteins.
33. Monitoring plasma processing steps with a sensitive Western blot assay for the detection of the prion protein.
34. HIV-1 membrane fusion mechanism: structural studies of the interactions between biologically-active peptides from gp41.
35. Structure-activity relationships of novel hematoregulatory peptides.
36. Potent inhibition of HIV type 1 infection of mononuclear phagocytes by synthetic peptide analogs of HIV type 1 protease substrates.
37. Efficacy of the hematoregulatory peptide SK&F 107647 in experimental systemic Candida albicans infections in normal and immunosuppressed mice.
38. In vivo modulation of hematopoiesis by a novel hematoregulatory peptide.
39. Synergistic drug interactions of an HIV-1 protease inhibitor with AZT in different in vitro models of HIV-1 infection.
40. V3 loop region of the HIV-1 gp120 envelope protein is essential for virus infectivity.
41. Human chromosome-dependent and -independent pathways for HIV-2 trans-activation.
42. Alteration of HIV-1 infectivity and neutralization by a single amino acid replacement in the V3 loop domain.
43. The chronically infected cell as a target for the treatment of HIV infection and AIDS.
44. Morphometric analysis of recombinant soluble CD4-mediated release of the envelope glycoprotein gp120 from HIV-1.
45. Human chromosome 12 is required for elevated HIV-1 expression in human-hamster hybrid cells.
46. Anti-GP 120 antibodies from HIV seropositive individuals mediate broadly reactive anti-HIV ADCC.
47. Stable indicator cell lines exhibiting HIV-1 tat function.
48. The effects of hybrid ribosome-binding-site variants on the expression of human interferon-beta in Escherichia coli.
49. Chemical synthesis and expression of a gene encoding HIV-1 TAT protein.
50. Polymorphism of the 3' open reading frame of the virus associated with the acquired immune deficiency syndrome, human T-lymphotropic virus type III.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.